Form 8-K - Current report:
SEC Accession No. 0001193125-25-002153
Filing Date
2025-01-06
Accepted
2025-01-06 16:01:28
Documents
14
Period of Report
2024-12-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d900848d8k.htm   iXBRL 8-K 32254
2 EX-10.1 d900848dex101.htm EX-10.1 53090
  Complete submission text file 0001193125-25-002153.txt   218957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20241231.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20241231_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20241231_pre.xml EX-101.PRE 10829
17 EXTRACTED XBRL INSTANCE DOCUMENT d900848d8k_htm.xml XML 3541
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 25510975
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)